Safety of IL17/23 Inhibitors in Patients with Psoriasis or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis

Published: 02-06-2020| Version 1 | DOI: 10.17632/pff4wtbwcd.1
Contributor:
yuwen su

Description

Supplemental figures and tables for 'Safety of IL17/23 Inhibitors in Patients with Psoriasis or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis'.

Files